GlassScriptPhysician profile
Kellie Soles
NPI 1104302256
$480.55
in general payments reported to CMS, 2019-2025
13 companies · $177 in 2025
The $177 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $303 · 2025: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $481.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $480.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $76.50 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $66.13 | 2024 | Wegovy |
| Pfizer INC. | $60.27 | 2024-2025 | |
| Lilly USA, LLC | $42.65 | 2024 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $41.30 | 2024-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Idorsia Pharmaceuticals US INC | $34.65 | 2024 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.75 | 2025 | Xifaxan |
| Amgen INC. | $29.88 | 2024-2025 | Otezla, Repatha, Otezla |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.55 | 2024 | Caplyta |
| Astellas Pharma US INC | $22.60 | 2025 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $18.42 | 2024 | Trintellix |
| Dexcom, INC. | $16.58 | 2024 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $15.27 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kellie Soles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.